Harry Kirsch has been Chief Financial Officer (CFO) of Novartis since 2013. He is a member of the Executive Committee of Novartis.
Mr. Kirsch joined Novartis in 2003 and, prior to his current position, served as CFO of the Pharmaceuticals Division (now known as the Innovative Medicines Division). He has been instrumental in focusing Novartis as a leading medicines company by overseeing key divestitures, the acquisition of GlaxoSmithKline’s oncology products in 2015, and the spin of Alcon into a public company in 2019. In prior assignments, he served as CFO of Pharma Europe and as Business Planning & Analysis Head of the Pharmaceuticals Division. Mr. Kirsch joined Novartis from Procter & Gamble (P&G) in the United States, where he was CFO of P&G’s global pharmaceutical business. Prior to that, he held finance positions in various categories of P&G’s consumer goods business, technical operations and Global Business Services organization.
Mr. Kirsch holds a diploma degree in industrial engineering and economics from the University of Karlsruhe in Germany. From 2015 to 2018, he represented Novartis on the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd.